RNAimmune
PrivateLast Round
Series A
Mar 29, 2022
Total Funding Raised
$39.35M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
RNAimmune is a biotechnology company specializing in mRNA-based therapeutics and vaccines aimed at addressing cancer, infectious, and rare diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RNAimmune Comparables
Compare RNAimmune with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Replicate Bioscience | 84% | |
| Providence Therapeutics | 82% | |
| Kernalbio | 81% |
RNAimmune Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 29, 2022 | ||||
| Seed | Apr 21, 2021 | ||||
| Angel | Aug 24, 2020 |
RNAimmune Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Terra Magnum Capital Partners | Angel |
| Rotating Boulder Fund | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 19, 2026
Monthly visitors increased 64% MoM.
- Mar 29, 2022
$27M round led by Sirnaomics.
RNAimmune Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about RNAimmune's valuation, stock price, and market status.
Is RNAimmune a public or private company?
RNAimmune is a private company.
What is the current stock price of RNAimmune?
RNAimmune is a private company with no public stock price. No recent secondary market data is available.
How much is RNAimmune worth (valuation)?
Valuation information for RNAimmune is not publicly available.
Can I buy RNAimmune stock?
RNAimmune shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was RNAimmune's last funding round?
RNAimmune's most recent funding round was Series A on March 29, 2022.
Who are the main investors in RNAimmune?
Key investors in RNAimmune include Terra Magnum Capital Partners, Rotating Boulder Fund.
Will RNAimmune IPO soon?
No public IPO plans have been announced for RNAimmune.
How can I track RNAimmune secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor RNAimmune's secondary market activity and sign up for updates.